Fundamental Analysis of IN8BIO INC(NASDAQ:INAB) stock

Fundamental Rating

Taking everything into account, INAB scores 1 out of 10 in our fundamental rating. INAB was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of INAB have multiple concerns. INAB has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

INAB had negative earnings in the past year.

In the past year INAB has reported a negative cash flow from operations.

INAB had negative earnings in each of the past 5 years.

INAB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

INAB has a worse Return On Assets (-142.07%) than 83.95% of its industry peers.

INAB's Return On Equity of -234.63% is on the low side compared to the rest of the industry. INAB is outperformed by 70.02% of its industry peers.

		Industry Rank	Sector Rank
ROA	-142.07%
ROE	-234.63%
ROIC	N/A

ROA(3y)-70.01%

ROA(5y)-156.5%

ROE(3y)-94.72%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

INAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, INAB has more shares outstanding

The number of shares outstanding for INAB has been increased compared to 5 years ago.

The debt/assets ratio for INAB has been reduced compared to a year ago.

2.2 Solvency

INAB has an Altman-Z score of -9.48. This is a bad value and indicates that INAB is not financially healthy and even has some risk of bankruptcy.

INAB has a Altman-Z score of -9.48. This is in the lower half of the industry: INAB underperforms 72.84% of its industry peers.

A Debt/Equity ratio of 0.04 indicates that INAB is not too dependend on debt financing.

With a Debt to Equity ratio value of 0.04, INAB perfoms like the industry average, outperforming 40.21% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF	N/A
Altman-Z	-9.48

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

INAB has a Current Ratio of 2.66. This indicates that INAB is financially healthy and has no problem in meeting its short term obligations.

INAB's Current ratio of 2.66 is on the low side compared to the rest of the industry. INAB is outperformed by 69.31% of its industry peers.

INAB has a Quick Ratio of 2.66. This indicates that INAB is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.66, INAB is doing worse than 67.90% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.66
Quick Ratio	2.66

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.90% over the past year.

EPS 1Y (TTM)35.9%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%34.78%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

INAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.99% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y39.91%

EPS Next 2Y30.08%

EPS Next 3Y20.57%

EPS Next 5Y24.99%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

INAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year INAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as INAB's earnings are expected to grow with 20.57% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.08%

EPS Next 3Y20.57%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for INAB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IN8BIO INC

NASDAQ:INAB (11/22/2024, 8:00:02 PM)

After market: 0.3282 +0.01 (+3.34%)

0.3176

0 (-0.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap23.02M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-142.07%
ROE	-234.63%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.66
Quick Ratio	2.66
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)35.9%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y39.91%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

IN8BIO INC (INAB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens